SG11202004540QA - Stable ascorbic acid compositions and methods of using the same - Google Patents
Stable ascorbic acid compositions and methods of using the sameInfo
- Publication number
- SG11202004540QA SG11202004540QA SG11202004540QA SG11202004540QA SG11202004540QA SG 11202004540Q A SG11202004540Q A SG 11202004540QA SG 11202004540Q A SG11202004540Q A SG 11202004540QA SG 11202004540Q A SG11202004540Q A SG 11202004540QA SG 11202004540Q A SG11202004540Q A SG 11202004540QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- same
- ascorbic acid
- acid compositions
- stable ascorbic
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 2
- 229960005070 ascorbic acid Drugs 0.000 title 1
- 235000010323 ascorbic acid Nutrition 0.000 title 1
- 239000011668 ascorbic acid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762588300P | 2017-11-17 | 2017-11-17 | |
| US201862684700P | 2018-06-13 | 2018-06-13 | |
| PCT/US2018/061686 WO2019099946A1 (en) | 2017-11-17 | 2018-11-16 | Stable ascorbic acid compositions and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004540QA true SG11202004540QA (en) | 2020-06-29 |
Family
ID=66539933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004540QA SG11202004540QA (en) | 2017-11-17 | 2018-11-16 | Stable ascorbic acid compositions and methods of using the same |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11497786B2 (en) |
| EP (1) | EP3710036A4 (en) |
| JP (2) | JP7339955B2 (en) |
| KR (1) | KR20200089702A (en) |
| CN (1) | CN111615395A (en) |
| AU (1) | AU2018367674A1 (en) |
| BR (1) | BR112020009910A2 (en) |
| CA (1) | CA3082900A1 (en) |
| IL (1) | IL274635A (en) |
| MX (2) | MX2020005087A (en) |
| PH (1) | PH12020550645A1 (en) |
| SG (1) | SG11202004540QA (en) |
| WO (1) | WO2019099946A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3541401A4 (en) | 2016-11-17 | 2020-07-29 | Renovion, Inc. | Treatment of respiratory tract diseases and infections with glutathione compositions |
| SG11202004540QA (en) | 2017-11-17 | 2020-06-29 | Renovion Inc | Stable ascorbic acid compositions and methods of using the same |
| CN111413492A (en) * | 2020-04-30 | 2020-07-14 | 山东大学 | Method and system for detecting novel coronavirus COVID-2019 pneumonia |
| EP3970718A1 (en) * | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
| WO2023014887A1 (en) * | 2021-08-04 | 2023-02-09 | The Trustees Of Indiana University | Methods of treating compromised lung function and assessing clinical improvement |
| CN113995744B (en) * | 2021-10-13 | 2023-03-17 | 温州肯恩大学 | Composition and antibacterial application thereof |
| WO2023133117A2 (en) * | 2022-01-04 | 2023-07-13 | Renovion, Inc. | Aqueous solution comprising a glutathione salt |
| WO2023141237A1 (en) * | 2022-01-20 | 2023-07-27 | Cell and Molecular Tissue Engineering, LLC | Methods and products to detect, minimize and treat trap-related tissue reactions and tissue injury associated with medical devices |
| WO2024016019A1 (en) * | 2022-07-15 | 2024-01-18 | Renovion, Inc. | Compositions and methods for treatment of subjects suffering from a sars-cov-2 infection |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2606903A (en) | 1944-03-29 | 1952-08-12 | Physiological Chemicals Compan | Ascorbic acid addition compound of sulfathiazole |
| US5070085A (en) | 1987-04-10 | 1991-12-03 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
| US4968716A (en) | 1987-04-10 | 1990-11-06 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
| US4861783A (en) | 1988-04-26 | 1989-08-29 | E. I. Du Pont De Nemours And Company | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases |
| US5304724A (en) | 1988-09-09 | 1994-04-19 | Entravision, Inc. | Tissue irrigating solution |
| US5238683A (en) | 1989-11-24 | 1993-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs |
| ATE144142T1 (en) | 1991-01-10 | 1996-11-15 | Transcend Therapeutics Inc | USE OF THIAZOLIDINE-4-CARBOXYLATE DERIVATIVES FOR THE TREATMENT OF LUNG DISEASES |
| US6764693B1 (en) | 1992-12-11 | 2004-07-20 | Amaox, Ltd. | Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants |
| US5626883A (en) | 1994-04-15 | 1997-05-06 | Metagenics, Inc. | Ascorbic acid compositions providing enhanced human immune system activity |
| NZ335401A (en) | 1996-11-01 | 2000-12-22 | Xoma Corp | Therapeutic uses of BPI protein products in cystic fibrosis patients |
| US6896899B2 (en) | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
| ATE448782T1 (en) | 1996-12-31 | 2009-12-15 | Antioxidant Pharmaceuticals Co | PHARMACEUTICAL GLUTATHIONE PREPARATIONS AND METHODS OF ADMINISTRATION SAME |
| US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US6415798B1 (en) | 1997-09-19 | 2002-07-09 | Thione International, Inc. | Antioxidants to neutralize tobacco free radicals |
| US5829449A (en) | 1997-09-19 | 1998-11-03 | Thione International, Inc. | Smoking products containing antioxidants |
| US6470894B2 (en) | 1997-09-19 | 2002-10-29 | Thione International, Inc. | Glutathione, green tea, grape seed extract to neutralize tobacco free radicals |
| US6228347B1 (en) | 1997-12-01 | 2001-05-08 | Thione International, Inc. | Antioxidant gel for gingival conditions |
| CA2339473A1 (en) | 1998-08-04 | 2000-02-17 | John V. Kosbab | Nutrient and therapeutic compositions for the treatment of cancer |
| US6312734B1 (en) | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| KR100390630B1 (en) * | 1999-07-02 | 2003-07-07 | 이희발 | Peritoneal dialysis solutions containing antioxidants |
| DE19935763B4 (en) | 1999-07-27 | 2006-03-02 | Jenning, Volkhard, Dr. | Composition of a redox system for the stabilization of retinoids in preparations for external use |
| US7045152B2 (en) | 1999-09-08 | 2006-05-16 | Duke University | Treating pulmonary disorders with gaseous agent causing repletion of GSNO |
| US20020037855A1 (en) | 2000-05-05 | 2002-03-28 | Fritz Stanislaus | Stabilized medicament containing cysteinyl derivatives |
| EP1282416A2 (en) | 2000-05-19 | 2003-02-12 | Progenics Pharmaceuticals, Inc. | Dehydroascorbic acid formulations and uses thereof |
| US6601580B1 (en) | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
| US6485950B1 (en) | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
| AU1122202A (en) | 2000-10-16 | 2002-04-29 | Univ Duke | Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| US20020165207A1 (en) | 2001-05-02 | 2002-11-07 | Richard Rosenbloom | Compositions and methods for the treatment of diabetic neuropathy |
| WO2002053161A1 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| DE60233140D1 (en) | 2001-05-02 | 2009-09-10 | Nitromed Inc | NITROSED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHOD OF USE |
| EP1474158B1 (en) | 2001-12-18 | 2009-10-14 | Brassica Foundation for Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes |
| AUPS019802A0 (en) | 2002-01-31 | 2002-02-21 | Chemstop Pty Ltd | Nutrient formulation |
| US20040229815A1 (en) | 2003-01-03 | 2004-11-18 | Nagasawa Herbert T. | Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug |
| US9539367B2 (en) | 2003-12-04 | 2017-01-10 | University Of Iowa Research Foundation | Gallium inhibits biofilm formation |
| US20050271726A1 (en) | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
| DE102004035113A1 (en) | 2004-07-20 | 2006-02-16 | Degussa Ag | Composition for treating symptoms of cystic fibrosis comprises alpha-lipoic acid or a derivative thereof as the sole active ingredient |
| US8349359B2 (en) | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
| ES2395555T3 (en) | 2004-11-07 | 2013-02-13 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
| CA2587883A1 (en) | 2004-11-17 | 2006-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma |
| US8703198B2 (en) | 2005-03-02 | 2014-04-22 | Aquatrove Biosciences | Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof |
| WO2006110552A2 (en) | 2005-04-12 | 2006-10-19 | Cleo Cosmetic And Pharmaceutical Co., Llc | Composition and method for in vitro preservation of corneal tissues |
| US20060258599A1 (en) | 2005-04-27 | 2006-11-16 | Melanie Childers | Methods and composition for the treatment of cystic fibrosis and related illnesses |
| WO2006125262A1 (en) | 2005-05-24 | 2006-11-30 | Environmental Biotechnology Crc Pty Limited | Methods and compositions for regulating biofilm development |
| CA2620123C (en) | 2005-08-24 | 2011-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis |
| AU2007249348C1 (en) | 2006-05-10 | 2013-01-17 | Laclede, Inc. | Compositions and methods for enzymatic treatment of lung disorders |
| US20080008694A1 (en) | 2006-07-05 | 2008-01-10 | Elgebaly Salwa A | Methods to prevent and treat diseases |
| US20100310541A1 (en) | 2007-05-25 | 2010-12-09 | Ironwood Pharmaceuticals, Inc. | Compositions and Methods for Reducing the Toxicity of Certain Toxins |
| WO2009001884A1 (en) | 2007-06-26 | 2008-12-31 | Kyowa Hakko Bio Co., Ltd. | Oxidized glutathione tablet |
| JP2011026204A (en) | 2007-11-26 | 2011-02-10 | Rei Furukawa | Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke |
| JP5406049B2 (en) | 2008-02-05 | 2014-02-05 | 協和発酵バイオ株式会社 | Method for improving storage stability of glutathione |
| US9289462B2 (en) | 2008-09-17 | 2016-03-22 | Terry Gage | Method for medical treatment utilizing glutathione |
| FR2941374B1 (en) | 2009-01-28 | 2011-03-11 | Alaxia | USE OF A SYNERGISTIC ASSOCIATION OF HYPOTHIOCYANITIS AND / OR HYPOHALITY IONS AND LACTOFERRIN FOR THE PREPARATION FOR THE TREATMENT OF MUCOVISCIDOSIS |
| WO2010099523A1 (en) | 2009-02-27 | 2010-09-02 | University Of Cincinnati | Method of treating reactive airway disease |
| GB0908174D0 (en) | 2009-05-13 | 2009-06-24 | Isis Innovation | Steroid containing composition and uses thereof |
| CN101987195B (en) | 2009-08-06 | 2012-07-18 | 重庆市力扬医药开发有限公司 | Reduced glutathione medicine absorbed through oral mucosa |
| IT1401504B1 (en) | 2010-08-02 | 2013-07-26 | Cattarini Mastelli | COMPOSITION INCLUDING GLUTATION AND REDUCTASE AND OXIDIZED GLUTATION |
| WO2012027603A2 (en) | 2010-08-26 | 2012-03-01 | Clarity Products, Limited Liability Company | Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2 |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| CN102100904B (en) | 2011-01-25 | 2013-04-24 | 成都卓阳生物科技有限公司 | Reduced glutathione percutaneous absorption preparation and preparation method thereof |
| US10328152B2 (en) | 2011-06-16 | 2019-06-25 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
| US20130084336A1 (en) | 2011-06-27 | 2013-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Enhanced nitric oxide delivery and uses thereof |
| CN102329370B (en) | 2011-09-22 | 2015-07-22 | 山东金城医药化工股份有限公司 | Method for preparing reduced glutathione monosodium salts |
| CA2925546C (en) | 2012-10-29 | 2022-06-14 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
| US20140234397A1 (en) | 2013-02-15 | 2014-08-21 | Lou Ann Brown | Treatment of klebsiella pneumoniae with liposomally formulated glutathione |
| EP2956153A4 (en) | 2013-02-15 | 2017-03-22 | Your Energy Systems, LLC | Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione |
| ITPD20130052A1 (en) | 2013-03-01 | 2014-09-02 | Enologica Vason S P A | VINIFICATION PROCEDURE AND PRODUCT FOR ENOLOGICAL USE ACT TO BE USED IN THE ABOVE WINE-MAKING PROCEDURE |
| WO2016037166A1 (en) | 2014-09-07 | 2016-03-10 | Yu Zhang | Novel anti-oxidant compositions and methods of delivery |
| WO2016067283A1 (en) | 2014-10-30 | 2016-05-06 | Rice Howard | Virucidal compositions comprising tannins for nasal and pulmonary administration |
| WO2016088116A1 (en) | 2014-12-05 | 2016-06-09 | University Health Network | Use of antioxidants as radio-protective agents |
| US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
| EP3484458A4 (en) | 2016-07-16 | 2020-04-15 | Lauranell Harrison Burch | Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces |
| EP3541401A4 (en) | 2016-11-17 | 2020-07-29 | Renovion, Inc. | Treatment of respiratory tract diseases and infections with glutathione compositions |
| SG11202004540QA (en) * | 2017-11-17 | 2020-06-29 | Renovion Inc | Stable ascorbic acid compositions and methods of using the same |
| EP3714881A4 (en) | 2017-11-21 | 2021-09-01 | Medoncare Pharmaceutical Co., Ltd | Combination product comprising dicycloplatin and preparation method and use thereof |
| EA202091396A1 (en) | 2017-12-07 | 2020-09-02 | РИВЕН АйПи ХОЛДКО ЭлЭлСи | COMPOSITIONS AND METHODS FOR TREATMENT OF METABOLIC CONDITIONS |
| AU2019365216A1 (en) | 2018-10-23 | 2021-06-10 | George Edward Hoag | Composition and method for treating the lungs |
-
2018
- 2018-11-16 SG SG11202004540QA patent/SG11202004540QA/en unknown
- 2018-11-16 EP EP18879332.7A patent/EP3710036A4/en active Pending
- 2018-11-16 MX MX2020005087A patent/MX2020005087A/en unknown
- 2018-11-16 US US16/764,781 patent/US11497786B2/en active Active
- 2018-11-16 BR BR112020009910-4A patent/BR112020009910A2/en unknown
- 2018-11-16 WO PCT/US2018/061686 patent/WO2019099946A1/en unknown
- 2018-11-16 CN CN201880086217.5A patent/CN111615395A/en active Pending
- 2018-11-16 AU AU2018367674A patent/AU2018367674A1/en active Pending
- 2018-11-16 CA CA3082900A patent/CA3082900A1/en active Pending
- 2018-11-16 JP JP2020545050A patent/JP7339955B2/en active Active
- 2018-11-16 KR KR1020207017215A patent/KR20200089702A/en not_active Application Discontinuation
-
2020
- 2020-05-13 IL IL274635A patent/IL274635A/en unknown
- 2020-05-15 PH PH12020550645A patent/PH12020550645A1/en unknown
- 2020-07-13 MX MX2023010248A patent/MX2023010248A/en unknown
-
2022
- 2022-10-07 US US17/938,861 patent/US11890315B2/en active Active
-
2023
- 2023-06-01 JP JP2023090905A patent/JP2023110019A/en active Pending
- 2023-12-21 US US18/392,459 patent/US20240131109A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020117840A3 (en) | 2022-04-22 |
| IL274635A (en) | 2020-06-30 |
| RU2020117840A (en) | 2021-12-17 |
| MX2020005087A (en) | 2020-08-13 |
| MX2023010248A (en) | 2023-09-15 |
| US11497786B2 (en) | 2022-11-15 |
| JP7339955B2 (en) | 2023-09-06 |
| US20230144527A1 (en) | 2023-05-11 |
| CN111615395A (en) | 2020-09-01 |
| JP2023110019A (en) | 2023-08-08 |
| WO2019099946A1 (en) | 2019-05-23 |
| AU2018367674A1 (en) | 2020-06-04 |
| US20200397849A1 (en) | 2020-12-24 |
| JP2021503497A (en) | 2021-02-12 |
| US20240131109A1 (en) | 2024-04-25 |
| CA3082900A1 (en) | 2019-05-23 |
| PH12020550645A1 (en) | 2021-04-19 |
| EP3710036A1 (en) | 2020-09-23 |
| KR20200089702A (en) | 2020-07-27 |
| US11890315B2 (en) | 2024-02-06 |
| BR112020009910A2 (en) | 2020-11-03 |
| EP3710036A4 (en) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2582482B (en) | CASZ compositions and methods of use | |
| HK1256726A1 (en) | Carrier-binding agent compositions and methods of making and using the same | |
| IL274635A (en) | Stable ascorbic acid compositions and methods of using the same | |
| ZA201707981B (en) | Compositions of obeticholic acid and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| IL286391A (en) | Fenfluramine compositions and methods of preparing the same | |
| EP3576782A4 (en) | Construct-peptide compositions and methods of use thereof | |
| PT3509638T (en) | Cannabidiolic acid esters compositions and uses thereof | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| IL258139A (en) | Nicotine formulations and methods of making and using the same | |
| HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| HK1250345A1 (en) | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same | |
| IL273988A (en) | Cannabidiol and chitosan compositions and methods of using the same | |
| IL259583A (en) | Collagen 7 compositions and methods of using the same | |
| EP3270985A4 (en) | Polypeptide compositions and methods of using the same | |
| IL274563A (en) | Methods of using and compositions containing dulaglutide | |
| IL275377A (en) | Compositions comprising stabilized oxygen and methods of forming the same | |
| GB201616491D0 (en) | Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same | |
| GB201511863D0 (en) | Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same |